In this blog, we reflect on the adoption of technology in translation and look through the lens of a linguist at some of the transformational changes in clinical trial translations. We asked experienced ICON Language Services linguists for their insights on how machine translation (MT) has transformed some of our workflows and the opportunities this technology brings to our working lives and our customers.
Love it or loathe it, machine translation is here to stay.
The current opinion on MT includes a wide spectrum of views and emotions. On one hand are the technology enthusiasts, keen to adopt the latest and greatest release at the earliest opportunity. On the other hand are the resisters, who push back the increasing advancements of change to well-established working practises. We are all human and have varying change acceptance curves. Where we all eventually agree is that technology, just like any tool, has great potential and great limitations, depending on the skills of the people wielding them. From a linguist’s perspective, we must ensure any adopted tool can capture the rich nuance of one of the pinnacles of evolution: language.
Machine Translation (MT) was not developed and adopted overnight. It took decades of effort to refine and perfect, but the stories surrounding its release often overlooked the extensive development process behind it. MT was introduced as a groundbreaking new concept, without fully acknowledging the history of the work that shaped it into the advanced tool it is today. It was also launched during a time of broader acceptance of transformational change, which helped speed up its adoption. At the same time, a wave of debate emerged — the term "machine translation" created an impression of simplicity in translation, leading to theories suggesting that human linguists might no longer be necessary. This is why myths about MT continue to circulate, and debates about its role persist.
How has MT changed clinical trial translations?
Some of us have been translators for long enough to remember when we relied on printed dictionaries and resources. Back then a rudimentary word processing system limited our ability to store, reuse and adapt our work. In a relatively short space of time, we have witnessed astronomical advances in technology that have transformed our industry, with the introduction of Computer-Assisted Translation (CAT) tools, MT, Neural MT and now Large Language Models (LLM) and generative AI (Gen AI) models.
On the surface, the translation process remains largely unchanged. Linguists utilise a CAT tool which displays the original text (in the source language) and the translation (in the target language) side-by-side. This leverages phrases and/or entire segments of previously translated text, for the linguist to review, amend and approve for use in the translation. This body of previously translated content, referred to as a Translation Memory (TM), is a valuable resource. The use of legacy wording allows the translator to work efficiently and ensures that language is used consistently. And it is at this stage that MT comes in.
As explained in a recent ICON blog, MT works alongside Translation Memories, using algorithms and machine learning models to generate an approximate translation in the desired language. The MT engines are regularly “trained”, learning from the corrections made by the linguists at post-editing stage. In this way, MT constantly improves the output quality and evolves the prediction algorithms. Essentially, when we receive a document, part of the content is leveraged from the Translation Memory and the remaining text is machine translated. Linguists are involved at every stage. We may not translate from scratch, but we edit the text provided. We do not use MT as a standalone feature or service in our area of work. It is also important to note that we use machine translation in custom engine setups that protect confidential content and do not share it outside our company or with the public.
How does MT measure up to the clinical trial industry’s high standards?
There are certain text types that are more suited for the use of MT: texts with shorter sentences and repetitions that do not overuse synonyms. Information documents and (patient-facing) clinical material are ideal candidates. Furthermore, with the improved efficiency MT brings, linguists can complete more words in the same amount of time, which means we work on more varied content and build up knowledge on different subjects. As in-house linguists the approach to overall linguistic quality assurance and asset management has changed. While the quality assurance process was traditionally aimed at work created by humans, we now focus on improving data provided by both machines and humans making it easier for the MT engines to learn.
The introduction of automation to the translation industry spotlights the very thing that attracted many of us to the trade: the fundamental role language plays in determining an individual’s personal and cultural identity. A word may have a given dictionary meaning, but how it is perceived and understood, and the context in which it should be used, can vary significantly. Its interpretation can change from country to country, culture to culture, region to region and even individual to individual. This is one of the things that MT still struggles with. While the dictionary meaning may be strictly correct, the usage of the word may not be appropriate and could cause confusion or offence in another context.
One of the areas MT does not (yet) handle well is the rendering of nuances of meaning and use of figurative, descriptive language. For example, the title of a patient recruitment text might invite participants by referring to their “Journey With Clinical Research”. This might generate a direct MT output such as “su viaje con investigación clínica” in Spanish. One of the challenges with this output is the direct translation of “journey” as “viaje” (travel). In this context “journey” is not meant as the physical act of travelling from one place to another, but the symbolic and emotional journey of a person living with a disease, encompassing their treatment and how it affects their life. The MT output does not convey any of this. It takes a human, with an understanding of what it means to be healthy or to have a disease, to produce a translation that reflects this. Our task as linguists is to ensure the data used to train the MT engines is of high-quality, so that the engines can start picking up on these subtle nuances eventually. As with any source text intended for translation and/or localisation, the general rule applies: the better the input, the better the translated end result. Clarity of meaning at source (both within a document and project-wide), consistency and grammatical accuracy are of paramount importance for a quality end product, especially when using MT.
Conclusion
Linguists’ working days are very different today from when some of our careers began with a bookshelf of dictionaries by our desks. None of us long to return to those analogue days with clunky word processers and limited possibilities. The combination of customised MT and CAT tools means that we still deliver translations of the highest quality for our customers, but today we do it more efficiently and in greater volumes. A specialised human linguist is essential to skilfully operate those tools, amending and adapting translations and ensuring they meet the rigorous quality standards of the clinical trials industry. For now, at least, machines cannot match the human mind’s ability to differentiate the many subtleties of language which depend on context and audience. From start to finish, linguists are vital to maintain the industry’s high standards by bringing their experiences – as translators and human beings – to the process of conveying important ideas through language.
Contact us to learn more about how we can support your language services needs.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
Exploring FDA guidance for modern Data Monitoring Committees
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
-
Central Nervous System
-
A mind for digital therapeutics
-
Challenges and opportunities in traumatic brain injury clinical trials
-
Challenges and opportunities in Parkinson’s Disease clinical trials
-
Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D
-
Key Considerations in Chronic Pain Clinical Trials
-
ICON survey report: CNS therapeutic development
-
A mind for digital therapeutics
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel